Sysmex Corporation (HQ: Kobe, Japan; President: Hisashi Ietsugu) has received the “Invention Award” in the 2011 National Commendation for Invention, sponsored by the Japan Institute of Invention and Innovation, for technologies related to its white blood cell classification and counting method and associated reagents. This was the second year in a row for Sysmex to receive a National Commendation for Invention. The award ceremony is scheduled to take place in Tokyo on Monday, June 20.
Classifying and counting white blood cells (including abnormal cells) is extremely important from the perspective of diagnosing disease. White blood cells are generally classified into five types: lymphocyte, monocyte, neutrophil, eosinophil and basophil. The ratio and number of these white blood cells may change as the result of disease. However, in testing with automated hematology analyzers, it was difficult to distinguish between normal and abnormal white blood cells, and the presence of abnormal cells makes accurate classification and counting difficult to achieve.
This invention resolves the issue through the preparation of a solution of red blood cells and the development of a dye compound. This compound substantially enhances fluorescent intensity by combining a hemolysis agent that renders the cells to be measured receptive to staining with the RNA included in the cells.
Simply mixing the reagent with a blood sample facilitates the classification and counting of five types of normal white blood cell, at the same time classifying and counting to a high degree of precision abnormal cells, such as immature white cells. This invention also enables the automatic counting of immature granulocytes, which previously had been problematic. The resulting immature granulocyte counts can be used in diagnosing bone marrow convalescence, serious infection, transplants of cancerous bone marrow and myelogenous leukemia.
As a result, extensive information on the measurement of normal and abnormal white blood cells can be provided as the result of a single measurement, contributing to the efficiency of medical care and the early detection of blood disorders. Through its incorporation into our mainstay fully automated hematology analyzers (such as the XN Series, XE Series, XT Series and XS Series), we will enable customers to regularly take advantage of this technology.
Going forward, Sysmex will continue to promote research and development that contributes to breakthroughs in healthcare and improvements in science and technology.
Example 1: Normal Blood Analysis: Automated Hematology Analyzer and New Reagent ![]() |
Example 2: Patient Blood Analysis: Automated Hematology Analyzer and New Reagent ![]() |